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Background: Array-CGH represents a comprehensive tool to discover genomic disease alterations that could
potentially be applied to body fluids. In this report, we aimed at applying array-CGH to urinary samples to
characterize bladder cancer.
Methods: Urinary DNA from bladder cancer patients and controls were hybridized on 44K oligonucleotide arrays.
Validation analyses of identified regions and candidates included fluorescent in situ hybridization (FISH) and
immunohistochemistry in an independent set of bladder tumors spotted on custom-made tissue arrays (n = 181).
Results: Quality control of array-CGH provided high reproducibility in dilution experiments and when comparing
reference pools. The most frequent genomic alterations (minimal recurrent regions) among bladder cancer urinary
specimens included gains at 1q and 5p, and losses at 10p and 11p. Supervised hierarchical clustering identified the
gain at 1q23.3-q24.1 significantly correlated to stage (p = 0.011), and grade (p = 0.002). The amplification and
overexpression of Prefoldin (PFND2), a selected candidate mapping to 1q23.3-q24.1, correlated to increasing
stage and tumor grade by means of custom-designed and optimized FISH (p = 0.013 and p = 0.023,
respectively), and immunohistochemistry (p ≤0.0005 and p = 0.011, respectively), in an independent set of
bladder tumors included in tissue arrays. Moreover, PFND2 overexpression was significantly associated with poor
disease-specific survival (p ≤0.0005). PFND2 was amplified and overexpressed in bladder tumors belonging to
patients providing urinary specimens where 1q23.3q24.1 amplification was detected by array-CGH.
Conclusions: Genomic profiles of urinary DNA mirrowed bladder tumors. Molecular profiling of urinary DNA
using array-CGH contributed to further characterize genomic alterations involved in bladder cancer progression.
PFND2 was identified as a tumor stratification and clinical outcome prognostic biomarker for bladder cancer
patients.
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Table 1 Demographic and histopathologic information of
the bladder cancer patients and controls providing
urinary samples utilized for DNA profiling using
oligonucleotide array-CGH
Bladder Cancer Patients
ID Gender a Age Stage Grade
105 HG M 65 pTA G1
125 HG F 51 pTA G1
130 HG M 54 pTA G1
136 HG M 58 pTA G1
138 HG F 70 pTA G3
75 HS M 75 pT1 G2
123 HG M 78 pT1 G2
131 HG M 81 pT1 G2
141 HG M 72 pT1 G3
127 HG M 79 pT2 G3
132 HG M 74 pT2 G3
139 HG M 69 pT2 G3
129 HG M 66 pT2 G3
100 HG M 78 pT4 G3
Controls
ID Gender a Age Pool Status
DNA 19/10 F 30 1 Healthy donor
76HS M 83 1 No evidence of disease
79HS F 73 1 & 2 Cystitis
111HG M 55 1 No evidence of disease
116HG F 61 2 Healthy donor
118HG M 61 1 & 2 No evidence of disease
135HG M 51 2 Healthy donor
143HG F 71 2 Healthy donor
a M, Male; F, Female.
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Bladder cancer represents the 4th most common ma-
lignancy among men and the 8th cause of male cancer
deaths. Approximately 90% of malignant tumors aris-
ing in the uroepithelium of the bladder are transitional
cell carcinomas (TCC) [1]. Currently, the diagnosis
and surveillance of bladder cancer is based on the in-
formation provided by cystoscopy, considered the gold
standard, in combination with urinary cytology find-
ings. The invasive nature of cystoscopy, still uncom-
fortable for a great number of individuals, together
with the subjective nature of urinary cytology, greatly
dependant on the skills of the pathologist and the
quality of the sample [2], triggers for the search of
non-invasive objective methods for bladder cancer.
Urinary specimens, in direct contact with bladder tu-
mors, represent easily attainable samples to explore
molecular events associated with tumor progression
and provide biomarkers for cancer detection, surveil-
lance and clinical outcome stratification.
Gains and losses of DNA copy numbers in specific
chromosomal regions are frequent and critical genomic
changes associated with tumor development and pro-
gression. These genomic imbalances can be detected by
conventional CGH on metaphase spreads [3], or DNA
sequences spotted into an array (array-CGH) [4]. In
bladder cancer, conventional CGH was applied in frozen
TCCs alone [5-9], or including squistosoma-associated
squamous cases [10]. Analyses were also performed
using paraffin-embedded TCCs alone [11-13], or inclu-
ding squamous tumors [10,14,15], and cell lines [16-18].
Array-CGH, using Bacteria Artificial Chromosome
(BAC) or oligonucleotide arrays, represents a sensitive
method for high-resolution analysis of genomic imba-
lances, able to detect small amplicons and deletions. In
bladder cancer, BAC arrays were applied in frozen bladder
tumors [19-24], and cell lines [25,26]. Oligonucleotide-
based array-CGH was utilized to define the DNA copy
number changes even in paraffin-embedded tumors [27].
These reports showed that array-CGH was widely ex-
plored in bladder tumor specimens and cell lines. A recent
report has applied a focused miniarray-CGH test to body
fluids [28]. In this study, we aimed at evaluating high-
throughput array-CGH profiling of urinary DNA of blad-
der cancer patients as a means contributing to further
characterize genomic alterations involved in tumor pro-
gression and identify potential bladder cancer biomarkers
(Additional file 1: Figure S1).
Methods
Urinary DNA specimens
Urinary samples belonging to patients with primary
bladder tumors (n = 14) were obtained following institu-
tional reviewed approved protocols at participatinginstitutions. Samples were collected in compliance with
the Helsinki Declaration, after written informed consent
according to SAF2009-13035 and SAF2012-40206 eth-
ical approvals. The presence of the disease was con-
firmed by cystoscopy, together with the histopathologic
information after surgical interventions. Urinary speci-
mens positive for bladder cancer were obtained from 5
pTa, 4 pT1, 4 pT2 and 1 pT4 cases (Table 1). Genomic
DNA from urine samples belonging to healthy donors
and individuals with no evidence of disease, were used to
generate two normal DNA reference pools (n = 8)
(Table 1). Urinary DNA was extracted using the QIAamp
DNA Micro kit (Qiagen, Hilden, Germany). Concentra-
tion and purity of DNA samples were determined with a
ND-1000 spectrophotometer (NanoDrop Technologies,
Wilmington, DE).
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Genomic DNA (250 ng) from urinary specimens (n = 22)
belonging to bladder cancer patients, healthy donors and
individuals with no evidence of disease (reference pools)
were hybridized against Human Genome CGH 44 k
oligonucleotide microarrays version B, (Agilent, Palo
Alto, CA). This array consisted of 44000 (60-mer) oligo-
nucleotide probes, 40,912 of them against known genes
and Expressed Sequenced Tag (ESTs), at a mean reso-
lution of 75 Kb. Urinary DNA from bladder cancer pa-
tients was labelled with Cyanine 5 (Cy5) and urinary
DNA reference pool with Cyanine 3 (Cy3). Arrays were
scanned at 670 and 570 nm for Cy5 and Cy3 respectively,
using the G2565BA Scanner (Agilent).
Array-CGH imaging and data analysis
Microarray images were transformed to fluorescence inten-
sities using the Feature Extraction Software, v9.5 (Agilent),
allowing spot gridding, quantification and local background
subtraction. Microarray data were visualized using the
CGH Analytics v3.3 software (Agilent). The hybridization
of the urinary samples was assessed according to the quality
control parameter Derivative Log Ratio (DLR) spread pro-
vided by this software. The DLR spread metrics estimated
the spread of log ratio differences between consecutive
probes along all chromosomes. Samples were proven to ex-
hibit a DLR spread lower than 0.3 log units and a signal to
noise ratio for each channel greater than 30.
Chromosome segmentation was carried out using the
smoothing algorithm from the InSilicoArray CGH soft-
ware at http://www.gepas.org (GEPAS, Valencia, Spain)
[29], which estimates the mean log10 ratio value of all
the probes belonging to a given chromosomal region,
and provides the Copy Number Value (CNV) of such
region. These CNVs were checked under the threshold
of +0.1 for gains and −0.1 for losses allowing the iden-
tification of the chromosomal aberrations in the urin-
ary specimens under study. Amplifications were defined if
consecutive probes spanning a gained region, showed a
CNV higher than 0.3979 (more than five DNA copies)
[29]. Finally, the CNVs were categorized as 0, 1 or −1
(indicating no change, gain or loss, respectively) in
order to identify minimal recurrent regions with over-
lapping gains or losses affecting different urinary speci-
mens. A region was considered to harbour a minimal
recurrent region if at least three consecutive probes
were simultaneously changed in at least two speci-
mens. Single-probe aberrations were not scored as
copy number changes. DNA copy changes observed in
the samples showing at least 80% of their sequence
overlapping with known polymorphisms included in
the Database of Genomic Variants were excluded from
the analyses (http://projects.tcag.ca/variation).Supervised hierarchical clustering
In order to evaluate the association of copy number
changes detected by array-CGH and clinicopathologic
variables, the minimal recurrent regions of gains and
losses were subjected to supervised hierarchical cluste-
ring using the POMELO tool from the ASTERIAS software
(http://www.asterias.bioinfo.cnio.es). Obtained p-values using
the analysis of variance (ANOVA) test were adjusted for false
discovery rates (FDR) corrections [30].
Tissue microarrays
We constructed different tissue microarrays including
triplicate cores of the paired bladder tumors belonging
to the patients providing urinary specimens and inde-
pendent sets of primary TCCs cases (n = 181) with avail-
able follow-up, recruited from several collaborating
clinical institutions. Samples were collected in compli-
ance with the Helsinki Declaration, after written informed
consent according to SAF2009-13035 and SAF2012-40206
ethical approvals. For tissue array construction, tumor tis-
sues were embedded in paraffin and five-μm sections were
stained with hematoxylin and eosin to identify viable,
morphologically representative areas of the specimen from
which needle core samples were taken, using a precision
tissue microarrayer (Beecher Instruments, Silver Spring,
MD). From each specimen, triplicate or quadruplicate
cores with diameters of 1.0 mm were punched and
arrayed on the recipient paraffin block. The distribution of
tumor stage among the bladder tumors spotted onto the
tissue arrays was: pT1 (78), pT2 (59), pT3 (26), pT4 (18),
while their tumor grade was: grade 2 (10), and grade 3
(171). Patients were treated surgically by transurethral re-
section in non-invasive lesions and cystectomy in muscle-
invasive tumors. Adjuvant therapy consisted of intravesical
instillations with the Bacille of Calmette-Guerin in non-
muscle invasive disease and cisplatin chemotherapy in
muscle-invasive tumors, respectively.
Fluorescence-in-situ-hybridization analyses (FISH)
FISH analysis was performed on the tissue arrays men-
tioned above. Four BACs covering the 1q23.3 region
where PFND2 maps: RP11-157H6, RP11-297K8, RP11-
1008K23, and RP11-136J10, were selected from UCSC
(http://genome-ucsc.edu.) and labelled using the Spectrum
Red 2’-deoxyuridine 5’-triphosphate (dUTP) (Vysis,
Downers Grove, IL) by nick translation with the CGH
Nick Translation kit (Vysis). Four independent BACs
mapping to 1p were selected as controls: RP11-199O1,
RP11-624A15, RP11-709H9, and RP11-473K14, and were
labelled with the Spectrum Green dUTP (Vysis). BACs
were obtained from the BACPAC Resource Center
(Oakland, CA, US). High hybridization efficiency and
specificity were confirmed by performing FISH on nor-
mal lymphocyte metaphase preparations.
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microscope (Olympus BX61, Olympus Corporation, Tokyo,
Japan). Images were captured and analysed using the
Cytovision image analysis system (Applied Imaging Ltd.,
New Castle, UK). Only discrete signals in nuclei with dis-
tinct nuclear border stained with 4’, 6-diamidino-2-
phenylindole (DAPI) were counted. Overlapping nuclei
were excluded from evaluation. Five different categories
were defined for classification and interpretation of FISH
results. The observation of two red and two green signals
per nucleus was considered ‘normal’ and categorized as ‘1’;
such pattern combined with three red spots in a similar
percentage was categorized as ‘2’; copy number ‘gains’ were
defined if three red spots were present in at least 50 % of
intact tumor nuclei, being categorized as ‘3’. Category ‘4’
was defined if there were similar percentages of nuclei
showing three than those with more than three red signals.
Finally, if at least 50% of the tumor cells doubled the red to
green spots ratio, the case was considered ‘amplified’ and
categorized as ‘5’.
Immunohistochemistry (IHC)
Protein expression patterns of PFND2 were assessed by IHC
analysis on the tissue arrays mentioned above (n = 181),
using avidin-biotin immunoperoxidase procedures [31]. A
goat polyclonal antibody against PFND2 from IMGENEX
(San Diego, CA) was applied at a 1:800 dilution. Ki67 was
assessed using a mouse monoclonal antibody diluted at
1:100 (clone MIB-1; DAKO, Glostrup, Denmark). The
absence of the primary antibody was used as negative
control. Diaminobenzidine was the final chromogen
and hematoxylin was the nuclear counterstain.
Cell lines and western blotting analysis
Nine bladder cancer cell lines derived from TCCs of the
bladder were obtained from the American Type Culture
Collection (Rockville, MD, US), grown, and collected
under standard tissue culture protocols. The specificity
of the antibody utilized for IHC mentioned above was
screened by Western blotting at 1:300 dilution using 75 μg
of lysate protein per lane. An alpha-tubulin antibody
(mouse monoclonal, 1:5000 dilution, Sigma- Aldrich, St.
Louis) was utilized as loading control.
Statistical methods
The association between gene and protein expression
measured on tissue arrays by FISH and IHC respectively,
and histopathologic stage and tumor grade was evaluated
using the non-parametric Wilcoxon-Mann–Whitney and
Kruskall-Wallis tests [32]. Associations with disease-
specific overall survival were estimated using the log-rank
test in those cases for which follow-up information was
available. Disease-specific overall survival time was
defined as the years elapsed between transurethralresection or cystectomy and death as a result of dis-
ease (or the last follow-up date). Patients who were
alive at the last follow-up or those lost to follow-up
were censored. There is no consensus on the cutoffs
for the immunohistochemical expression for protein
expression patterns for prefoldin. The number of cells
expressing a cytoplasmic sublocalization was analyzed
continuously. The cutoff value for low, medium and
high expressing cases was specified at the median per-
centage score of positive cytoplasmic tumor cells
resulting in a value of intensity of 2 (++). Prefoldin inten-
sity was then analyzed taking the cutoff of 2 (++) when
considered as a categoric variable. Survival curves were
plotted using the Kaplan-Meier methodology [32]. Statis-
tical analyses were performed using the SPSS statistical
package v17.0 (SPSS Inc., Chicago, IL).
Results
Reproducibility Assessment of Array-CGH using Urinary
DNA. Owing to the limited amount of DNA extracted from
urinary specimens, the minimum quantity of initial urinary
DNA necessary to obtain reliable CGH estimations was ini-
tially tested. Reverse labelling (dye swaps) analyses were
performed comparing 250 versus 500 ng as the starting
amount of genomic DNA. Gains and losses using 500 ng
were also detected using 250 ng (Additional file 2: Figure
S2A). The optimal correlation found between 250 versus
500 ng revealed that the use of the lowest DNA amount
(250 ng) did not prevent to detect any relevant copy number
changes, providing reliable genomic profiling array-CGH.
The potential influence of varying the source of non-
neoplastic DNA in the reference pool from several do-
nors was tested. Two urinary pools including different
healthy donors and individuals with no evidence of dis-
ease (confirmed by cystoscopy), were compared by
array-CGH (Additional file 2: Figure S2B). The lack of
significant copy number changes among these pools
when performing reverse labelling hybridizations re-
vealed that variations in the source of non-neoplastic
DNA in the reference pool did not prevent detecting
relevant copy number changes of bladder cancer pa-
tients. Overall, these analyses revealed that array-CGH
was feasible in bladder cancer urinary specimens using a
low initial amount of DNA. Additionally, variations in
the source of healthy normal urothelium in the reference
pool did not impact on the identification of bladder can-
cer associated genomic changes.
Identification of genomic imbalances in urinary specimens
The high-resolution genomic analysis for the urinary
specimens belonging to bladder cancer patients was ini-
tially assessed using the CGH Analytics (Figure 1A), and
the InSilicoArray CGH softwares (Figure 1B). Additional
file 3: Figure S3 provides visualization for all of them.
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Figure 1 Array-CGH detected genomic imbalances in urinary specimens. A. Summary ideogram given by the CGH Analytics software for a
representative urinary belonging to a patient with a pT1G2 bladder tumor (case 131HG). Average log2 ratio values along the chromosomes are
represented by the red line. Displacement of the tracing of this red line to the right or left represents genomic gains or losses, respectively. The
ideograms are ordered from chromosome 1 to 22, including chromosomes X and Y as well B. Detailed genomic DNA profile image for the same
case obtained using the InSilicoArray CGH software. Average log10 ratio values of the CNVs along the chromosome are represented by the blue
line. Displacement of the tracing of this blue line to the right or left represents genomic gains or losses, respectively. The profiles are ordered
from chromosome 1 to 22, including chromosomes X and Y as well.
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regions of gain and loss among the urinary specimens
(Table 2). The group of urinary specimens belonging to
patients with papillary pTa lesions did not show gains
and harboured 30% of the losses. Non muscle-invasive
pT1 cases displayed the highest number of copy number
changes, showing 86.96% of the gains (20/23), and 70% of
the losses (7/10). Muscle-invasive pT2+ cases displayed
17.39% of the gains (4/23), and 10% of the losses (1/10).
Regarding tumor grade, urines belonging to patients
with grade 1 tumors did not show genomic gains, and
harboured 30% of the losses (3/10). Grade 2 cases
displayed the highest number of CNVs, showing 86.96% of
the gains (20/23), and 70% of the losses (7/10). Urines
belonging to grade 3 cases had 17.39% of the 23 gains
(4/23), and 20%of the losses (2/10).
The CNVs for the regions of gain and loss were revised
to identify overlapping (minimal recurrent) gained and
lost regions among the urinary specimens, highlighted inTable 2. The most recurrent genomic alteration was the
gain at 1q23.3-q24.1, followed by gains at 1q21.2-q21.3,
1q24.2-q24.3 and 5p13.33-p12, and losses at 10p15.3 and
11p15.5. The complete set of known genes mapping to
these minimally recurrent regions is provided as
Additional file 4: Table S1. Overall, these analyses re-
vealed the utility of array-CGH as a high-throughput
technique to identify genomic changes associated with
bladder cancer using urinary specimens. Additionally, they
revealed that the gain at 1q21-q24 was of potential clinical
interest for urinary biomarkers discovery.
Supervised hierarchical clustering identified 1q23.3-q24.1
differentially expressed region regarding histopathologic
variables
Supervised hierarchical clustering was performed to
identify top discriminatory genomic imbalances among
the minimal recurrent regions of gain and loss associ-
ated with tumor stage and grade, by means of ANOVA
Table 2 Gains and losses detected by array-CGH (ordered by the CNVs) in each case
CHROMOSOMAL REGIONS OF GAINS
1st Probe Name Chromosome band (Ensembl) Start position CNV Cases Stage Grade Number of probes
A_14_P115961 19q13.12-q13.2 Chr19:041377289 0.41069 123HG pT1 G2 152
A_14_P108613 20q13.13-20q13.2 Chr20:048671089 0.3998 123HG pT1 G2 52
A_14_P123794 2p23.3 Chr2:027502237 0.31715 139HG pT2 G3 5
A_14_P201430 20q12-q13.12 Chr20:039082984 0.30745 123HG pT1 G2 101
A_14_P130062 19q12 Chr19:034522544 0.28517 123HG pT1 G2 18
A_14_P118037 15q25.1 Chr15:077932195 0.27764 139HG pT2 G3 8
A_14_P110668 8p12-p11.21 Chr8:036027406 0.26755 123HG pT1 G2 120
A_14_P200557 19q13.42 Chr19:060805118 0.21635 139HG pT2 G3 5
A_14_P128880 19p13.11 Chr19:017431158 0.20428 123HG pT1 G2 68
A_14_P107769 15q21.2 Chr15:048417834 0.19587 123HG pT1 G2 13
A_14_P119367 17q12 Chr17:034473380 0.17478 123HG pT1 G2 32
A_14_P114294 11q12.3 Chr11:061766567 0.16714 123HG pT1 G2 44
A_14_P108406 10p15.3-p12.31 Chr10:001070037 0.16666 123HG pT1 G2 217
A_14_P103528 1q21.2-q21.3 Chr1: 146938814 0.16485 123HG pT1 G2 141
131HG pT1 G2
A_14_P126330 1q24.2-q24.3 Chr1:163305648 0.13374 123HG pT1 G2 122
131HG pT1 G2
A_14_P126727 1q23.3-q24.1 Chr1:157564589 0.12808 75HS pT1 G2 116
123HG pT1 G2
131HG pT1 G2
A_14_P102488 6p21.1 Chr6:041358388 0.12681 123HG pT1 G2 83
A_14_P135779 18p11.32-p11.21 Chr18:000170229 0.12203 123HG pT1 G2 176
A_14_P105338 3p26.1-p21.33 Chr3:006615679 0.12067 123HG pT1 G2 529
A_14_P101810 5p13.33-p12 Chr5:000148243 0.11948 123HG pT1 G2 440
132HG pT2 G3
A_14_P200670 16q11.2-q12.1 Chr16:045172598 0.11639 123HG pT1 G2 49
A_14_P105981 22q12.2-q13.1 Chr22:030417113 0.10517 123HG pT1 G2 162
A_14_P126618 7q21.2-q33 Chr7:091892016 0.10403 123HG pT1 G2 631
CHROMOSOMAL REGIONS OF LOSSES
1st Probe Name Chromosome band (Ensembl) Start position CNV Cases Stage Grade Number of probes
A_14_ P135773 13q14.2-q14.3 Chr13:047555252 −0.26486 132HG pT2 G3 66
A_14_ P139280 11p15.5 Chr11:000283643 −0.18187 130HG pTA G1 6
75HS pT1 G2
A_14_ P134493 10p15.3 Chr10:000138206 −0.16050 136HG pTA G1 9
138HG pTA G3
A_14_ P110624 9p24.3-p21.2 Chr9:000204367 −0.15219 123HG pT1 G2 324
A_14_ P128129 10q11.22-q21.1 Chr10:047954413 −0.12787 123HG pT1 G2 65
A_14_ P110069 2q37.1-q37.3 Chr2:233099731 −0.12386 131HG pT1 G2 167
A_14_ P119514 8p23.3-p21.2 Chr8:000181530 −0.12229 123HG pT1 G2 309
A_14_ P109355 16p11.2-p11.1 Chr16:031804884 −0.11781 123HG pT1 G2 11
A_14_ P112424 7q22.1 Chr7::099453161 −0.11741 130HG pTA G1 75
A_14_ P103261 5q33.3-q35.1 Chr5:159767536 −0.11684 123HG pT1 G2 95
The minimal recurrent regions of gains and losses are highlighted in bold.
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found differentially expressed between the urinary speci-
mens (p = 0.011, FDR =0.068) (Figure 2A). 1q23.3-q24.1
was also the region differentially expressed regarding
their tumor grade (p = 0.002, FDR = 0.016) (Figure 2B).
Overall, these results confirmed the clinical relevance of
the gain at 1q23.3-q24.1 as a minimal recurrent region
associated with clinicopathologic variables of bladder
cancer (Figure 3A). Localization of the minimal recur-
rent regions of aberration in the urinary specimens asso-
ciated with histopathologic variables prompted us the
search for genes potentially involved in bladder cancer
in the most recurrent region at 1q23.3-q24.1. This re-
gion harboured a set of genes commonly gained in 3 out
of the 14 urinary samples analyzed, with 116 probes
showing this gain (Table 2). Among these genes identi-
fied in this region showing the highest log-ratio gains
(Additional file 4: Table S1), PFND2 was selected for fur-
ther validation analyses (Figure 3B).
PFND2 is associated with tumor progression and clinical
outcome of bladder cancer patients
The gain of PFND2 detected by array-CGH, and its pro-
tein overexpression were initially evaluated by FISH and






Figure 2 Supervised clustering of the minimal recurrent regions reve
histopathologic variables. The genomic profiles of the urinary specimens
POMELO software based on: A. tumor stage, and B. tumor grade. The figur
and loss (L), with these histopathologic variables including the information
p-values and FDRs.belonging to the bladder cancer patients providing uri-
nary specimens. The cases showing PFND2 amplification
in the urinary specimen displayed amplification in the
paired bladder tumor by FISH (Additional file 1: Figure
S1B) and also protein overexpression by IHC (Additional
file 1: Figure S1C). Paired normal urothelium specimens
showed a normal pattern of hybridization (data not
shown, similar to Figure 4A). The association between
FISH and IHC observations with clinicopathologic vari-
ables was then evaluated on tissue arrays containing in-
dependent sets of bladder tumors (n = 181). For FISH
analyses, three main hybridization patterns were observed:
normal (Figure 4A), gains (Figure 4B), and amplifications
(Figure 4C). For IHC analyses, the intensity of PFND2 im-
munostaining was categorized from 1 (Figure 4D), to 3
(Figure 4E). Interestingly, tumor stage was significantly as-
sociated with the gene amplification observed by FISH
(p = 0.013), and the protein overexpression of PFND2
observed by IHC (p ≤ 0.0005). Tumor grade was also
associated with PFND2 amplification (p = 0.023), and
its overexpression (p = 0.011). PFND2 amplification and
protein overexpression were significantly associated between
them (Kendall’s tau = 0.125, p = 0.034), and with increased
proliferation as measured by Ki67 staining (Kendall’s tau τ =
0.223, p ≤ 0.0005, and τ= 0.433, p ≤ 0.0005, respectively).Chr 1q23.3-q24.1
Chr 1q23.3-q24.1
aled the association of the gain at 1q23.3- q24.1 with
belonging to bladder cancer patients were clustered using the
es illustrate the association of the minimal recurrent regions of gain (G)
of the first gene mapping at each region and their respective
A B
Prefoldin
Figure 3 Array-CGH analysis showing the 1q23.3- q24.1 region that harbors the PFND2 gene. A. The ideogram of chromosome 1 for the
urinary specimen 131HG belonging to a pT1G2 bladder tumor is shown to the left. The central red tracings represent the mean signal ratio of
each of the clones along the chromosome generated by the CGH Analytics software. Displacement of this red line to the right of the centre
indicates relative genomic gains. B. Gene view of the gain at 1q23.3-q24.1 displaying probes as dots. The color of each dot represents normal
(black) or gains (red). The gain of PFND2 identified by array-CGH is highlighted.
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overexpression had shorter disease-specific survival
than those with low expression (log rank, p < 0.0005,
Figure 4F). Overall, FISH and IHC validation analyses
on tissue arrays containing an independent large set of
bladder tumors served to associate PFND2 amplifica-
tion and overexpression with histopathologic variables
of tumor progression and clinical outcome of bladder
cancer patients.
Discussion
Since its introduction, array-CGH served to discover
underlying molecular mechanisms leading to tumorige-
nesis and cancer progression and the identification of
potential biomarkers and therapeutic target candidates.
The novelty of this study deals with the application of
genome-wide copy number analysis to urinary speci-
mens. Interestingly, array-CGH served to detect genomicalterations specific of bladder cancer in non-invasive spe-
cimens, including several previously reported alterations
of known biological and clinical relevance in bladder tu-
mors, and the precise refinement of the localization of
copy number changes. Such genomic alterations were
proven to be specific of bladder cancer cells on matching
bladder tumors of the urinary specimens, and on inde-
pendent sets of bladder tumors by means of FISH and
IHC analyses. Thus, the present study showed that array-
CGH on urinary specimens could mirrow bladder tumors
and provided further information contributing to characterize
bladder cancer progression and identifying candidate bio-
markers for bladder cancer.
Several technical issues in our experimental design
were critical to allow detecting relevant genomic
changes in urinary specimens. First, the high size of
the array (44000 probes) in combination with its reso-
lution (75 Kb) allowed a refined screening of genomic
A B C
D E F
Figure 4 PFND2 expression patterns are associated with tumor progression and clinical outcome. A, B, C. Representative FISH images of
PFND2 on tissue arrays containing bladder tumors (n = 181) showing cases with normal (A), gained (B), and amplified (C) hybridization patterns.
D.E. Representative immunostainings by immunohistochemistry showing cases with low (+) (D) and high (+++) (E) intensity of PFND2
cytoplasmic expression on tissue arrays. F. Kaplan-Mayer curve survival analysis indicating that a cytoplasmic protein expression of PFND2 with
medium (++) or high (+++) intensity measured by immunohistochemistry on tissue arrays was associated with shorter disease-specific overall
survival (log rank, p ≤0.0005).
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starting genomic DNA (250 ng). Second, the chosen
pool of urinary DNA including normal healthy donors
and individuals without evidence of disease was appropri-
ate enough to detect genomic changes characteristic of
bladder tumors, regardless the variation of the control in-
dividuals providing urinary specimens. The choice of the
reference DNA extracted from uroepithelial cells of
healthy individuals or patients with benign conditions
without bladder cancer is justified since this source of
non-neoplastic uroepithelial cells are exposed to the urin-
ary environment, similarly to the DNA obtained from the
bladder cancer patients. The pool served to exclude non
bladder cancer specific genomic changes due to normal
cells present in the urine allowing the use of a conserva-
tive threshold for CNVs.
The high-resolution array-CGH analyses identified
genomic gains and losses between urinary DNA belong-
ing to bladder cancer patients and controls, many of
which were previously reported using conventional CGH
and array-CGH analyses on bladder tumor samples and
cell lines. Finding genomic changes previously reportedin bladder tumors provided confidence to our working
hypothesis by which urinary specimens belonging to
bladder cancer patients may mirrow genomic alterations
present in bladder tumors. The gains we identified
within minimal recurrent regions at 1q and 5p; and the
amplifications that we found in these urinary specimens
at 19q and 20q, the minimally recurrent regions of loss
at 11p and 10p; and those showing the highest loss
CNVs at 13q and 9p, were previously reported in blad-
der cancer cells and tumors [5-8,10-16,18,19,21,23-41].
Our study allowed the novel refinement of the localization
of copy number changes in several regions including the
gain at 19p13.11 or the loss at 10p15.3 among the most
differentially changed and minimally recurrent regions. In
a few urinary specimens, especially in cases with muscle-
invasive tumors, small chromosome regions, previously
reported to be altered in bladder cancer were not detected
using the oligonucleotide array-CGH platform. In addition
to the different type of bladder tumor analyzed in such
studies (stage and differentiation patterns), this observa-
tion could be associated with a lower proportion of
tumor cells as compared to the DNA corresponding to
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cancer patients, which could be considered a potential
limitation. Another explanation could be related to the
potential presence of multiple clones in the urinary
specimens [42], which could dilute the detection of
cancer cells with genomic alterations, so that regions
with few aberrant cancer cells could not be scored as
copy number changes because of our conservative ap-
plied cutt-off [43]. In the urinary specimens analyzed,
higher numbers of genomic alterations were observed
in non-invasive pT1 lesions as compared to invasive
tumors. The lower number of genomic alterations ob-
served in muscle-invasive tumors could be related to
the common solid pattern of growth of advanced tu-
mors towards the inner muscular layer not allowing a
high proportion of cancer cells to reach the urine as
compared to the frequent papillary growth pattern to-
wards the urine in non-invasive lesions.
In the present study, the most frequent genomic alter-
ations detected in the urinary DNA were at the long
arm of chromosome 1, with three different minimal re-
current regions of gain mapping at 1q21.2-q21.3,
1q23.3-q24.1, and 1q24.2-q24.3. Chromosome 1q gain was
frequently reported by conventional CGH in bladder tu-
mors: frozen TCC [5,6,8,36,38], paraffin-embedded TCC
[11-13], and cell lines [16,18]. More recently, the applica-
tion of array-CGH platforms allowed a precise mapping of
the 1q gained regions in TCCs [19,21], adenocarcinomas
[27], and cell lines [25]. Gains at 1q21.2-q21.3 were
detected in muscle-invasive and squamous cells [25]. The
1q23.2-q24.1 region was found gained in muscle-invasive
cells [25], and amplified in pT1 tumors [11,12]. At the
1q24.2-q24.3 region, gains were detected in TCCs [19], be-
ing such amplification at this region described in pT1
[11,12,21], and muscle-invasive bladder tumors [21]. The
simultaneous gains and amplifications at these three re-
gions at chromosome 1q were also described in TCC tu-
mors [36], in schistosoma-associated TCCs [14], in TCC
and SCC regardless of its association with squistosoma in-
fections [10]; and even in rare small cell carcinomas of the
bladder by conventional CGH [39]. Similarly to our results
in urinary specimens, gains at 1q21-q24 were reported in
pT1 but not in pTa TCCs [11,13,36], an observation
suggesting that this region may carry candidate genes in-
volved in progression into muscle-invasive disease. The
novelty of our report deals with the precise refinement of
gains at this chromosomal region using oligonucleotide
arrays together with the identification of such alterations
in urinary specimens.
Localization of minimal recurrent regions of aberra-
tion in the urinary samples prompted us the search for
genes potentially involved in bladder cancer progression.
Losses were most often observed in early stages (pTa),
whereas chromosomal gains became the most frequenttype of aberration in more aggressive pT1 tumors, as
previously reported [36]. Although bladder cancer sub-
classification was not the main objective of our study be-
cause of the limited number of specimens analyzed, the
supervised hierarchical clustering of the minimal recur-
rent regions highlighted 1q23.3-q24.1 as a relevant
gained region in the urinary DNA belonging to bladder
cancer patients regarding their histopathologic tumor
stage and grade. PFND2 was selected as one of the top-
ranked genes mapping at this region for which probes
and antibody were available for further validation. Al-
though this chromosome arm was previously described
to be altered in bladder cancer by conventional CGH
and array-CGH, as summarized above, to our know-
ledge, PDND2 had not been reported to be differentially
expressed in bladder cancer. PFND2 is a chaperone
heterooligomer protein involved in the folding of its tar-
get proteins [44,45]. This is relevant in cancer research
since members of the actin-related protein family requir-
ing the PFND2 pathway for their proper maturation play
a role in a variety of key cellular events, including orien-
tation of the spindle during mitosis, nuclear migration
[46], membrane polarity and endocytosis [47], or tran-
scriptional regulation [48,49]. The amplification and
overexpression results presented in this report correlat-
ing between them and with increased proliferation rates
are consistent with the upregulation of members of the
PFND2 protein family in cells and tumors of different
origin such as glioblastoma [50], breast [51], pancreatic
[52], or colon [53], where they are believed to play an
oncogenic role [54-56]. With this biological relevant infor-
mation, PFND2 was selected because of availability of re-
agents to be optimized for its assessment in bladder
tumors. Our study showed that urinary DNA reflected the
alterations present in the tumor since validation analyses
confirmed PFND2 to be amplified (Additional file 1: Figure
S1B) and overexpressed (Additional file 1: Figure S1C) on
paired bladder tumors of such urinary specimens. Consist-
ent with the identification of PFND2 as one of the genes
belonging to a region differentially gained regarding tumor
stage and grade, the DNA and protein expression patterns
of PFND2 were significantly associated with increasing
tumor stage and grade in an independent large set of blad-
der tumors spotted on tissue arrays by two independent
analytical methods at the DNA and protein level. Further
research is warranted to dissect its biological role in blad-
der cancer using appropriate in vitro and in vivo models.
Conclusions
PFND2 was identified as a candidate biomarker in bladder
cancer. Importantly, PFND2 overexpression in uroepithelial
malignancies suggested its potential utility as a tumor
stratification and clinical outcome prognostic biomarker.
Furthermore, its detection in urinary specimens suggests
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complementary adjunct of urinary cytology or as a protein
biomarker for the diagnosis and follow-up of patients
affected by uroepithelial malignancies.Additional files
Additional file 1: Figure S1. Experimental design. Array-CGH. A. Urinary
DNAs were subjected to array-CGH to identify genomic copy number
differences between bladder cancer patients (n = 14) and control
individuals (n = 8). Validation analyses. Two different approaches were
applied to evaluate the association of a selected candidate gene
mapping at such genomic imbalances with tumor progression and other
clinicopathologic variables. B. FISH analyses were optimized to validate
the copy number gain of the candidate gene PFND2 on paraffin
embedded tumors paired to the urinary specimens (a representative case
is shown) spotted on tissue arrays that also contained independent sets
of bladder tumors (n = 181). C. In addition, IHC analyses were carried out
on the paired tumors of the urinary specimens under analyses (a
representative case is shown), and on the above mentioned tissue arrays.
These FISH and IHC analyses served to validate associations of PFND2
with clinicopathologic variables. D. Western blot analyses were performed
using protein extracts from nine bladder cancer cell lines derived from
TCCs of the bladder of early stage (RT4), low grade (5637), invasive (T24,
J82, UM-UC-3, RT112, EJ138), metastatic (TCC-SUP), and squamous cell
carcinoma (ScaBER), to confirm the specificity of the PFND2 antibody
utilized in the study. The antibody was accepted because of displaying a
single predominant band at the expected molecular weight (16 KDa).
Moreover, invasive and metastatic cell lines derived from advanced
bladder tumors showed higher PFND2 expression than those derived
from early stage and low grade tumors.
Additional file 2: Figure S2. Evaluation of the reproducibility of array-
CGH on urinary DNA. A. Summary ideogram given by the CGH Analytics
software for one representative example comparing array-CGH results
using 250 ng versus 500 ng as initial amount of DNA. Average log2 ratio
values along the chromosomes are represented by the red (250 ng) and
blue (500 ng) lines. Displacement of the tracing of these red and blue
lines to the right or left represents genomic gains or losses, respectively,
which display in parallel. B. Genomic profile given by the InSilicoArray
CGH software comparing the hybridizaton of two independent reference
urinary pools labelled against each other. The two urinary pools consisted
of eight samples from healthy donors and individuals with no evidence
of disease. Average log10 ratio values of the CNVs along the chromosome
are represented by the blue line. Displacement of the tracing of this blue
line to the right or left represents genomic gains or losses, respectively.
Lack of displacement represents similar genomic profiles of the reverse
labeled pools. The profiles are ordered from chromosome 1 to 22,
including chromosomes X and Y as well.
Additional file 3: Figure S3. Urinary genomic DNA profiles obtained by
array-CGH for all the urinary specimens of the bladder cancer cases
under analyses ordered by tumor staging and presented as individual
ideograms given by the CGH Analytics software. Moving average log2
ratio values along the chromosome are represented by the red line.
Displacement of the tracing of this red line to the right or left represents
genomic gains or losses, respectively. The ideograms are ordered from
chromosome 1 to 22, including chromosomes X and Y.
Additional file 4: Table S1. Complete set of known genes mapping to
the minimally recurrent regions.Abbreviations
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